Wishing everyone a safe and joyous holiday season! Looking forward to an amazing 2023!
In a study published in Scientific Reports, Draper scientists tested and evaluated a batch of kidney-chips in an instrumented, high-throughput microenvironment in a lab-friendly footprint. They discovered a new indicator of toxicity in kidney-chips, an advance in the science that has the potential to reduce the financial burden of drug failures in pharmaceutical development.
It’s been said that imagination has no age. Must be true - Draper has been an innovation hub for almost 90 years. We invite you to scroll through our timeline to see our people’s most notable accomplishments in each decade – you’ll discover innovations in national security and space on through biotechnology and strategic systems. That proud legacy fuels our push forward today.
“Navigating in the lighting conditions and terrain of the lunar South Pole will be challenging,” said Brett Streetman, a space systems engineer at Draper who works on NASA’s Artemis mission. “Safety-focused navigation will enable a precise landing and allow the astronauts to explore the terrain safely and return to the lander vehicle with fewer potential complications.”
Babies born with heart valve defects will have as many as 3 to 5 open heart surgeries before adulthood to replace prosthetics as they grow. Draper is addressing that challenge by developing the first heart valve that can grow with the patient and most recently the team has developed an alternative to suturing the device to a bioprosthetic valve.
Draper is excited to announce that we have been selected by NASA to deliver a suite of three NASA-sponsored science payloads to the Schrödinger basin on the lunar surface. Schrödinger basin is on the far side of the Moon—a first for NASA. Looking forward to leading a team with ispace, inc., General Atomics, and Systima Technologies, Inc.!
Draper is going to the Moon – again! We’re thrilled to be part of the NASA Artemis I Mission, working on all 5 aspects of the mission: Space Launch System, Orion, Gateway, Commercial Lunar Payload Services and the Human Landing System.
Big news! Draper built and successfully demonstrated the first model of the human lung capable for assessing the efficacy of SARS-CoV-2 therapeutics in its PREDICT96 system! “A major limiting factor in the development of antiviral treatments for COVID-19 and other respiratory viral infections such as influenza is a lack of preclinical models capable of providing data predictive of human clinical responses at large scale. Draper’s PREDICT96-ALI allows researchers, who require human-equivalent efficacy data, to rapidly test drug candidates across diverse patient populations simultaneously,” Christine Fisher, Virologist and Bioengineer at Draper.
Draper recently hosted the Defense Department's Deputy Chief Technology Officer for Science and Technology (S&T), Barbara McQuiston, for a tour of our facilities in Cambridge.
Draper is excited to announce that, Dr. Jerry Wohletz, a senior executive at BAE Systems, Inc., has been selected as our next President and CEO.
Check out your Company Bowl for anonymous work chats.
